1-[(3aR,4R,6R,6aR)-6-[dideuterio(hydroxy)methyl]-2,2,3a-trimethyl-6,6a-dihydro-4H-furo[3,4-d][1,3]dioxol-4-yl]pyrimidine-2,4-dione | 1365634-61-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-[(3aR,4R,6R,6aR)-6-[dideuterio(hydroxy)methyl]-2,2,3a-trimethyl-6,6a-dihydro-4H-furo[3,4-d][1,3]dioxol-4-yl]pyrimidine-2,4-dione
• CAS: 1365634-61-2
• 化学式: C₁₃H₁₈N₂O₆
• 分子量: 300.28
• InChiKey: NYJFNNHCMMZARK-ZXNRGUBLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  97.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-[(3aR,4R,6R,6aR)-6-[dideuterio(hydroxy)methyl]-2,2,3a-trimethyl-6,6a-dihydro-4H-furo[3,4-d][1,3]dioxol-4-yl]pyrimidine-2,4-dione 在 N-甲基咪唑 、 水 、 三氟乙酸 作用下， 以 乙腈 为溶剂， 反应 24.5h， 生成 5'-dideuterated 2'-C-methyluridine 5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate
  参考文献：
  名称：

  SUBSTITUTED NUCLEOTIDE ANALOGS

  摘要：

  本文披露了磷酸硫代酯核苷类似物，合成磷酸硫代酯核苷类似物的方法，以及利用磷酸硫代酯核苷类似物治疗病毒感染、癌症和/或寄生虫病等疾病和/或症状的方法。

  公开号：

  US20120071434A1
• 作为产物：
  描述：

  (3aR,4S,6R,6aR)-tert-Butyl 6-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2,6a-trimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylate 在 硼氘化钠 、 溶剂黄146 作用下， 以50.83%的产率得到1-[(3aR,4R,6R,6aR)-6-[dideuterio(hydroxy)methyl]-2,2,3a-trimethyl-6,6a-dihydro-4H-furo[3,4-d][1,3]dioxol-4-yl]pyrimidine-2,4-dione
  参考文献：
  名称：

  SUBSTITUTED NUCLEOTIDE ANALOGS

  摘要：

  本文披露了磷酸硫代酯核苷类似物，合成磷酸硫代酯核苷类似物的方法，以及利用磷酸硫代酯核苷类似物治疗病毒感染、癌症和/或寄生虫病等疾病和/或症状的方法。

  公开号：

  US20120071434A1

文献信息

• DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20140309164A1

  公开（公告）日：2014-10-16

  Deuterated nucleoside analogs of Formula (I) and the pharmaceutically acceptable salts thereof are provided by this disclosure The variables, e.g., B 1 , Y, R 1 , R 2 , R 3 , R 3 ′, R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 carry definitions set forth in the disclosure. Compounds of Formula (I) are deuterated at one or more positions and the deuterium enrichment at each deuterated positions is at least 50%. Compounds and salts of Formula (I) are useful for treating viral infections, including HCV infections.

  本公开提供了式（I）的氘代核苷类似物及其药用盐。变量，例如B1、Y、R1、R2、R3、R3'、R4、R5、R6、R7、R8和R9在本公开中有定义。式（I）的化合物在一个或多个位置上被氘代，且每个氘代位置的氘富集度至少为50%。式（I）的化合物和盐对治疗病毒感染，包括HCV感染，具有用处。
• STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT
  申请人：Deshpande Milind

  公开号：US20160016986A1

  公开（公告）日：2016-01-21

  5′-Deuterated nucleosides and nucleotides and modifications thereof are provided for use in medical therapies, including as antiviral, anti-tumor and anti-neoplastic agents. In one embodiment, compounds, methods and uses are provided for the treatment of hepatitis C, RSV, HSV and other viral diseases in a host, including a human.

  提供了用于医疗疗法的5'-氘代核苷和核苷酸以及其修饰，包括作为抗病毒、抗肿瘤和抗肿瘤剂。在一个实施例中，提供了化合物、方法和用途，用于治疗丙型肝炎、RSV、HSV和其他病毒性疾病在宿主中，包括人类。
• HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20140309189A1

  公开（公告）日：2014-10-16

  A deuterated nucleoside analog of the formula and the pharmaceutically acceptable salts thereof are provided by this disclosure. The disclosure also includes pharmaceutical compositions comprising a compound or salt of the formula and a carrier. Compounds and salts of this formula are useful for treating viral infections, including HCV infections. A method for treating a host afflicted with hepatitis C or other disorders is also presented that includes administering an effective treatment amount of a nucleoside or nucleotide that has deuterium with at least 50% enrichment at the 5′-position of the nucleoside or nucleotide.
• US9447132B2
  申请人：——

  公开号：US9447132B2

  公开（公告）日：2016-09-20